Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Monsanto Company (NYSE: MON) could drop to about $92 if the potential deal with Bayer AG (ADR) (OTC: BAYRY) fails to take off.
In May, Germany's Bayer offered to buy Monsanto for $62 billion, or $122 a share. Monsanto rejected the offer terming it as "incomplete and financially inadequate," but said it was open to engage further in negotiations.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"We think it would take $135–$140/shr (implies 16.6x–17.2x our new '17 EBITDA) for MON to open its books. While the likelihood of some kind of a deal has increased, we think the possible downside share price risk is ~$92 without a deal (based on ~19x Seed EPS and ~10x Ag Productivity EPS)," analyst P.J. Juvekar wrote in a note.
Juvekar noted there are only a few strong agricultural chemical partners left for consolidation.
"BASF or Sumitomo Chemical are possibilities for some kind of deal including JVs, in our view," the analyst continued.
Rating And Justification
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
However, Juvekar maintains Neutral rating on Monsanto, citing industry uncertainty as agricultural fundamentals are bouncing along the bottom.
"Seed pricing did not hold up during 2016 amid tough competition, resulting in lower top-line growth and profitability. The guidance for '17 is softer and we do not see a turnaround in seed pricing until the grain cycle improves," Juvekar highlighted.
As such, the analyst slashed 2016 EPS estimate by $0.20 to $4.40 versus consensus estimate of $4.54.
That said, Juvekar added that Monsanto does have a few positives for 2017 including a $200 million benefit from the lack of Xtend costs ($100 million) and lower cost of goods sold ($100 million).
The company expects positive price lift next year, but "we are not fully convinced until we see how this year's crop harvest impacts grain prices."
Juvekar raised the target price to $112 from $94 based on increased probability of a potential transaction.
At time of writing, shares of Monsanto fell 1.86 percent to $101.49.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.